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ABSTRACT
Introduction “What effective ways of motivation, 
support and technologies help people with cystic fibrosis 
improve and sustain adherence to treatment?” was 
identified as one of the James Lind Alliance Priority Setting 
Partnership’s top 10 research questions in cystic fibrosis 
(CF). Using electronic questionnaires, we aimed to gain a 
deeper understanding of this research priority.
Method The work was led by the steering group 
representative of the UK CF community consisting of 
patients, carers and healthcare professionals (HCPs). 
Electronic questionnaires were completed over a 4- week 
period and promoted via online forums such as Twitter, 
the UK CF Trust and US CF Foundation websites and via 
professional networks. Analysis of the closed questions 
was completed using Microsoft Excel, with keyword 
analysis and the final thematic analysis completed using 
NVivo software.
Results There were 313 respondents; 176/313 (56%) 
were from people with CF and their families. HCPs 
comprised of 10 professional groups accounting for 
137/313 (44%) of respondents, with global involvement 
of participants with the majority from the UK. Common 
themes identified as impacting on adherence included: 
having no time, treatment burden, competing life demands, 
fatigue and the patient’s general health. Having a routine 
was identified as the most frequently used motivational 
strategy, valued by both the patient and professional 
community. However, some strategies were valued more 
by HCPs than used in practice by patients; these included 
the use of short- term goal setting and technology use.
Conclusion Adherence to treatment is crucial, however 
it is often suboptimal and strategies valued by HCPs to 
promote adherence are not always shared by patients. To 
promote adherence clinicians and researchers should be 
mindful that in a condition where treatment burden and 
time pressures are considerable, any interventions should 
focus on simplifying care and reducing treatment burden.
INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive 
multisystem disorder requiring a demanding 
daily regimen which may include airway 
clearance, inhaled therapies, pancreatic 
enzyme replacement therapies (PERT) and 
nutritional supplements.1 In the UK there 
are 10 000 people living with the condition, 
of which 40% are under the age of 16 years, 
with a predicted life expectancy of 47 years for 
those born in 2017.2 In the USA this number 
is 34 000.3 The formation of specialised CF 
centres in conjunction with improvements in 
respiratory treatments, better nutrition and the 
development of cystic fibrosis transmembrane 
conductance regulator (CFTR) modulator 
therapies have improved clinical outcomes 
for patients. The associated treatment burden 
is high with patients typically spending two to 
two and a half hours a day on their treatment 
regimens.4 5 Treatment adherence is crucial, 
with low adherence associated with increased 
pulmonary exacerbations, hospitalisations and 
lower respiratory function.6 However, adher-
ence rates in CF are suboptimal.6
In a recent global James Lind Alliance 
(JLA) Priority Setting Partnership exercise, 
the CF patient and clinical community jointly 
Key messages
 ► This study further explored one of the top 10 James 
Lind Alliance Priority Setting Partnership questions 
“What effective ways of motivation, support and 
technologies help people with cystic fibrosis improve 
and sustain adherence to treatment?”
 ► Treatment burden in cystic fibrosis (CF) is high and 
this affects adherence. We have highlighted the 
common themes impacting on adherence and the 
strategies used by both the patient and clinical CF 
community to improve this, including the role of dig-
ital technology.
 ► Through our work we have also demonstrated areas 
for future research which will be of benefit to the 
patient, clinical and research CF community.
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identified the top 10 clinical research questions important 
to the CF community.7 The following question was included 
in the top 10; “What effective ways of motivation, support 
and technologies help people with cystic fibrosis improve 
and sustain adherence to treatment?”. To gain a deeper 
understanding of this research priority question we under-
took an online survey to gain views from the CF community.
We aimed to first understand the challenges people with 
CF (pwCF) face with regards to adherence and second to 
summarise the motivation and support strategies used in 
promoting adherence. We aimed to better understand 
the views of the patient CF community and their fami-
lies and to determine if these views differed from those 
of healthcare professionals (HCPs). In addition, tech-
nology is having an increasing role within healthcare and 
its importance has been recognised by the World Health 
Organisation (WHO).8 Our final aim through explora-
tion of this question was to explore the role of technolo-
gies in promoting treatment adherence in CF.
METHODS
Data collection
This work was led by a steering group representative of the 
UK CF community consisting of pwCF, parents of pwCF 
and multidisciplinary HCPs. An electronic questionnaire 
was co- produced with contributions from steering group 
representatives using SurveyMonkey (http://www. survey-
monkey. com) and comprised of both closed questions 
and narrative free- text responses (online supplementary 
file 1). This was broadly separated within the survey into 
the three main areas of interest with regards to adher-
ence: motivation, support and technology. The survey 
was open to pwCF, their friends and families and HCPs 
for a period of 4 weeks (March to April 2019) and was 
inclusive of all ages. There were separate streams for lay 
and professional respondents to complete. Participants 
were asked to agree to the privacy policy prior to taking 
part and General Data Protection Regulation (GDPR) 
guidance was used for the management of any person-
ally identifiable data. The survey was promoted on 
Twitter using the twitter handle @questionCF as well as 
by the group @CFAware, the UK CF Trust, the US CF 
Foundation and via professional networks. This work was 
supported by the UK CF Trust under the title ‘James Lind 
CF2’. The University of Nottingham Research Ethics 
Committee deemed the original JLA work to not require 
ethical approval and this was an extension of this work.
Data analysis
Data were captured automatically by SurveyMonkey and 
downloaded to Microsoft Excel for quantitative data and 
NVivo qualitative data software package (QSR Inter-
national) for the free- text comments. Informed by an 
analytical approach previously developed by the group9 
a structured, iterative approach to data analysis was used 
which incorporated descriptive statistics, qualitative 
content analysis and qualitative thematic analysis.
Descriptive statistics were generated for the closed 
response questions and the word frequency function 
of the NVivo package was used to perform a content 
analysis10 of those questions which offered a free- text 
response. Semantically linked words (ie, tired, tiring) 
were combined in the counts and words such as ‘adher-
ence’ and ‘motivation’ were removed (their presence in 
the question artificially increasing their count). These 
quantitative data were merged and reviewed for each 
area of interest (motivation, support, technology). This 
was particularly useful with regards to identifying the 
types of technology used.
Synthesis of the data identified simple trends within 
the focus of answers and constituted an initial phase 
of thematic analysis.11 From the thematic analysis we 
identified areas of interest (termed codes) and overar-
ching ideas which might explain them (termed themes). 
Following this, all free- text responses were reviewed and 
mapped to these codes/themes. Given the variations in 
the quality and quantity of the free- text responses, qual-
itative data could be mapped to multiple codes/themes. 
Additional codes/themes were also created in response 
to novel comments. To ensure consistency, the coding 
was validated by two authors to ensure appropriateness of 
interpretation. Throughout, attention was paid to both 
frequent codes and key themes as well as for minority 
opinions and novel perspectives on the research question. 
Data generated by professionals and non- professionals 
(pwCF, parents of pwCF, and so on) were considered 
separately to allow comparison across these groups.
RESULTS
Demographics
In total, 313 responses were received; of which 176/313 
(56%) were from pwCF and their families and 137/313 
(44%) were from HCPs. Among the lay community 
Table 1 Professional demographics of healthcare 
professionals completing the survey. Healthcare 
professionals represented 10 professional groups
Professional group
Number 
responses Percentage
Physiotherapist 28 20.4%
Dietitian 28 20.4%
Psychologist 22 16.1%
Researcher 14 10.2%
Social worker 11 8.0%
Nurse 10 7.3%
Respiratory paediatrician 7 5.1%
Respiratory physician 7 5.1%
Pharmacist 3 2.2%
Junior doctor 2 1.5%
Unknown demographic 5 3.6%
Total 137
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103/176 (58%) responses were from pwCF, 70/176 
(40%) from a parent of a child or children with CF 
and 3/176 (2%) from another relative or friend. HCP 
responses comprised 10 professional groups (table 1), of 
which dieticians and physiotherapists both accounted for 
20% of responses. Not all respondents answered every 
question and so we have included the denominator where 
we present raw numbers. The majority of respondents 
(159/222, 72%) were from the UK with 52/222 (23%) 
from the USA and the remainder from Europe, Canada, 
Australia and New Zealand. The median age of pwCF was 
22 years (1 to 74 years).
Support
Both groups recognised the importance of support being 
available from a variety of sources (figure 1A). Immediate 
family and the CF team were identified as key support 
networks for pwCF in both quantitative and thematic 
analysis. These were also identified as positive support 
networks by HCPs, in addition to a minority also identi-
fying mental health services as a key area of support.
When asked if they were able to talk honestly with their 
CF team about adherence, 127/149 (85%) of pwCF and 
their families agreed. Most (98/151, 65%) felt they were 
well supported and their team understood their treat-
ment demands. However, the thematic analysis for this 
question revealed that there was greater expression of 
negative comments compared with positive responses 
relating to their CF team. Included within this were the 
feelings of letting their team down or feeling judged 
about their treatment adherence. In addition, others 
described that although their CF team were supportive, 
they did not fully understand the associated treatment 
burden or complexities of the disease (Quotes 1 and 2).
Quote 1, pwCF: I have absolute confidence in our 
team's academic knowledge of the disease and what 
it requires, but since none of them live it, I'm not 
entirely sure they fully grasp what the burden of care 
can truly be for patients and families.
Quote 2, pwCF: I feel great support when I'm doing 
it. I don't always feel that support when I'm not doing 
it. There's a tendency to think that I don't understand 
why this is important or that I am not trying hard 
enough. I have to explain it's a process of changing a 
whole system and that's incredibly difficult… It's not 
lack of motivation or lack of education/knowledge. I 
get it. I just can't get it done.
Motivation
Among pwCF and their families, 65/158 people (41%) 
reported full weekly treatment adherence, while 18% 
reported adherence to treatment less than half of the 
week. Within the lay community the most common 
Figure 1 (A) “Who supports you with your CF?” was answered by 147 people from the patient and carer community to help 
build a picture of support networks in CF. (B) Lay community (151 respondents) and HCPs (105 respondents) responses into 
motivation strategies used to promote adherence. CF,cystic fibrosis; HCPs, healthcare professionals.
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theme identified impacting on adherence was ‘having 
no time’ which encompassed competing work and 
school commitments. Free- text comments relating to the 
node ‘No Time’ was used 111 times, with an additional 
40 coded to ‘Competing Commitments’. Other factors 
were associated treatment burden including equipment 
cleaning and preparation time, working outside their 
usual routine, the patient’s general health and tiredness 
(Quote 3). In addition, a small number discussed mental 
health; although this was to a lesser extent than HCPs.
Quote 3, Family member with CF: Sometimes we're 
just tired—tired of setting up and breaking down 
equipment; tired of soaking and sterilising pieces; 
tired of figuring out how to fit treatments into our 
social activities as a family.
Our survey showed that 102/104 (98%) of HCPs incor-
porated asking about barriers to adherence into their 
consultations, however time constraints were identified 
as a factor preventing this occurring at every interaction. 
A minority felt that this wasn’t always appropriate to do at 
every consultation, for example, if focussing on alterna-
tive goals or instead choosing to focus on encouragement 
and what a patient had done well.
Figure 1B illustrates motivating techniques either 
used by pwCF and their families or promoted by HCPs. 
Both groups acknowledged that having a routine was 
important and was the most commonly identified strategy 
for promoting adherence; used by 116/151 (77%) 
patients and 93/105 (89%) of HCPs. It was also the most 
commonly coded strategy relating to adherence in the 
free- text comments. However, there were also discrep-
ancies between the two groups with some motivational 
strategies valued more highly by HCPs than by pwCF and 
their families. This was most apparent with short- term 
goal setting 85/105 (81%) versus 42/151 (28%), respec-
tively, and using electronic devices 76/105 (72%) versus 
34/151 (23%), respectively. A negative view of technology 
by a pwCF (Quote 4) included:
Quote 4, pwCF: I don't use health / med trackers as it 
just feels like another thing to have to manage (input 
data, more alarms etc).
Positive influential factors on adherence identified 
by patients through thematic analysis were: shortening 
preparation and treatment times such as time steri-
lising equipment; making treatments more portable or 
disposable; and having more physical support with their 
treatments at home. Comments relating to cleaning 
and sterilising equipment were coded 29 times. Free- 
text comments from HCPs highlighted that they valued 
patient- led goal setting; identifying health beliefs and 
patient- specific barriers; and motivational interviewing 
in promoting adherence.
The majority of pwCF and their families (144/151, 
95%) said they understood exactly what their treatments 
were for; 131/151 (87%) felt that this made adherence 
easier. Also, a number of patients described that education 
made them more ‘motivated’ to take their treatments 
and valued the importance of being informed. Never-
theless, it was suggested that treatment knowledge does 
not always reduce the treatment burden (Quote 5), while 
others felt that they didn’t receive adequate education. 
HCPs also valued highly the use of education to increase 
adherence through understanding.
Quote 5, pwCF: I know the importance but often 
doesn't make it easier or less exhausting to do.
Technology
In addition to the frequency of electronic device use 
varying between the two groups, the types of technolo-
gies preferred also differed (figure 2A). HCPs promoted 
the use of devices for monitoring (73/137, 53%), elec-
tronic reminders (64/137, 47%) and Apps (applica-
tions) (61/137, 45%), however only 35/176 (20%) of 
pwCF reported using Apps and 32/176 (18%) using elec-
tronic devices in the closed question responses. Instead 
most used technology for monitoring of their condition 
through the use of data tracking nebulisers and smart 
watches (49/176, 28% of lay respondents).
Among patients who did use digital technology, 
‘Reminders’ and its synonyms were the most frequently 
used words by pwCF and their families (used 38 times), 
with 59 responses coded to the node ‘Technology – 
Reminders’. For example, using timers or Apps to 
remind themselves to take medications or complete 
treatments, with some also linking these data to smart 
watches. Tracking of their condition was also discussed 
including tracking of their physical parameters, medica-
tions, trends and activity levels. This was enabled through 
the use of fitness watches such as Fitbit and Apple watches 
which were also used to promote exercise.
However, in contrast with the closed questions, for 
those who used technology, thematic analysis showed 
a greater emphasis on the use of Apps. The words App 
or Apps were used 69 times in responses. Apps was the 
most frequently used word relating to technology. A 
small number of pwCF used technology to order repeat 
prescriptions.
In keeping with the descriptive analysis of the closed 
responses, thematic analysis was largely positive from 
HCPs in regard to technology, who felt remote moni-
toring of a condition, including real- time feedback 
in the case of data tracking nebulisers was beneficial. 
Conversely, some professionals felt this level of adher-
ence monitoring was too invasive, describing it as ‘puni-
tive and exposing’ while others reflected on the lack of 
evidence base behind technology in CF (Quote 6).
Quote 6, HCP: I don't specifically recommend any 
(besides using phone for reminders) because none 
have proven efficacy. In absence of efficacy, it falls on 
patient's personal experience
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Figure 2B highlights the variations in data sharing 
practices from technology reported between pwCF and 
their CF team. Participants were able to select several 
responses. Our data show that there is a discrepancy over 
the perceived amount of data shared between pwCF and 
HCPs. There are also differences in perception over how 
these data are used to amend treatment plans. A higher 
proportion (45/72, 63% HCPs and 46/57, 81% pwCF) 
felt that pwCF kept their data to themselves for their 
own health monitoring while 39/72 (54%) HCPs versus 
19/57 (33%) pwCF felt that pwCF shared their data with 
their CF team. However, a larger percentage of HCPs 
believe that their patients shared their data with their CF 
team allowing them to adapt their treatment plan to what 
was done in practice by pwCF (38/72, 53% vs 8/57, 14%, 
respectively). The consensus among HCPs was that data 
are owned by the patients to be shared as they wished 
but was beneficial for providing an objective measure of 
adherence and to adjust treatment plans.
Perhaps unsurprisingly, HCPs were more aware of 
trials relating to technology than their patients. One in 
10 patients were aware of trials relating to technology. 
The most commonly identified trials by both groups were 
CFHealthHub12 and Project Fizzyo (ISRCTN51624752).13 
Both groups identified CF- specific Apps able to combine 
multiple aspects of CF care in one place, for example, 
calorie counting, medication reminders and monitoring 
as an area of future research interest relating to tech-
nology, with some HCPs expanding that these should be 
developed in conjunction with pwCF. The lay commu-
nity also suggested other trials including home moni-
toring of pulmonary function testing and physiological 
observations (heart rate/saturations), virtual clinics and 
trials involving physiotherapy. HCPs also expressed that 
current technology had limited evidence for its use in CF 
(Quote 7).
Quote 7, HCP: I think there is an amazing opportunity 
to use technology to promote adherence. However, 
this has to be well thought through and evidence 
based. Merely providing adherence data won’t 
improve adherence unless it is backed by evidence- 
based adherence support.
Figure 2 The use of digital technologies in CF. (A) Technologies used by the lay community (176 people) to help manage 
their treatment regimen versus what HCPs believe their patient’s to be using (137 people). (B) Views of how patients share 
their data that they collect from using digital technology versus what HCPs believe happen to these data. Respondents were 
able to select multiple responses. CF,cystic fibrosis; HCPs, healthcare professionals; pwCF, people with CF.
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DISCUSSION
This study had global involvement of pwCF, their fami-
lies and HCPs and through the use of a web- based survey 
collected their views on which motivation strategies, 
support networks and technologies help people with cystic 
fibrosis improve and sustain adherence to treatment. The 
current study confirms our previous work which showed 
that treatment burden in CF is high and patients, their 
families and HCPs recognise this as a barrier to adher-
ence.5 Patients described the relentlessness of the condi-
tion and identified that additional competing demands, 
such as from school and work, were barriers to adherence. 
Related themes were having no time (including time for 
preparation and cleaning of equipment) and tiredness. 
The high associated treatment burden in CF has been 
well described, with treatments typically taking two to two 
and a half hours to complete,4 5 needing adaptation and 
adjustment as the nature of the condition changes.
In this study and in our previous work we highlight that 
the most burdensome treatments identified by patients 
were the most likely to be omitted.5 However, other 
research has suggested that there is not always a clear 
relationship between objective treatment burden and 
adherence. This was demonstrated by Ball et al who found 
that teenagers with CF were most adherent to treatment 
during school- term weekdays, despite this being a time 
when there were many competing demands.14 Thus, the 
authors concluded there was value in integrating treat-
ments into a daily routine.
Routine has been shown to be advantageous in adher-
ence in CF. Hoo et al15 found that patients with higher 
levels of adherence had the highest habit scores, lower 
median intravenous antibiotic days and a trend towards 
higher forced expiratory volume in one second compared 
with those with low adherence. Habit formation is advan-
tageous as it reduces the need for conscious effort. 
Within our study both groups recognised the importance 
of having a routine and acknowledged that adherence 
was reduced when routine was disrupted.
In this study treatment burden is frequently given by 
participants as a reason for non- adherence. However, it 
is also possible that some respondents may have been 
reluctant to give a full explanation for their reasons for 
non- adherence. Drabble et al16 demonstrated that for 
patients who gave ‘forgot’ as a reason for non- adherence 
the underlying reasons for forgetting differed between 
high and low adherers. With regard to treatment burden, 
this may be a more acceptable rationalisation for some 
pwCF to disclose than the underlying reason for their 
non- adherence. We hope that through the anonymity of 
the survey this was minimised. In addition, perception of 
treatment burden can be influenced by coping strategies 
used. Work in type 1 diabetes17 found that patients with 
a maladaptive coping style to treatments (ie, avoidant 
coping) had greater levels of diabetes- specific distress. 
This resulted in amplifying the perception of their 
treatment burden followed by a deterioration in their 
self- management and glycaemic control. This may also 
be relevant for some pwCF with a similar coping style, 
thus amplifying an already significant treatment burden. 
Furthermore, where ‘burden’ is given as an explanation 
of suboptimal adherence, a behavioural change approach 
might interpret this as indicating the challenge faced by 
pwCF in establishing a sustainable routine in the face of 
a complex system.18
Our study found that CF education was valued and 
patients recognised the importance of being well 
informed, helping them to stay motivated when the 
immediate benefits were not seen. However, it was felt 
that education did not always relieve treatment burden. 
Education to improve self- management and adherence is 
used in a number of chronic conditions, with a number 
of self- management education strategies used in CF since 
the 1990s.19 Evidence of self- management education in 
CF however is still poor. A Cochrane review19 found that 
there was insufficient quantity or quality of evidence 
based on current trials to draw any firm conclusions 
around its role in CF, with further trials needed. It did 
acknowledge that there was some limited evidence that 
improved knowledge may result in a positive change to a 
small number of behaviours in CF.
The use of digital technology is a rapidly growing area 
within healthcare and its importance recognised by the 
WHO.8 Its use in CF has increased over the last 20 years 
yet there is currently limited evidence of its efficacy in 
improving long- term adherence in CF.20 This study has 
highlighted that although technology is being used by a 
group within the CF community to aid treatment manage-
ment; it is promoted more by HCPs than used in practice 
by the majority of pwCF at present.21 In addition, the 
types of technologies preferred by pwCF can be different 
to what is recommended by their HCPs. In particular 
the use of Apps provided interesting data. Although 
closed text responses reported relatively low use of Apps, 
thematic analysis provided more of an insight into their 
use than was captured by the closed question alone. Apps 
was the most frequently used word in relation to types of 
technologies used, with its use mainly linked to providing 
reminders. In addition, CF- specific Apps capable of 
combining multiple aspects of care was identified as an 
area of research interest. Studies such as MyCyFapp22 for 
patients with CF- related pancreatic insufficiency goes 
some way to addressing this research area. Its App has 
multiple functions including allowing the user to calcu-
late their optimal PERT dosing, complete symptom 
scoring and providing nutritional education. However, to 
our knowledge, there is no CF- specific App supported by 
trial data which allows patients to self- manage all aspects 
of their CF care in one place. Home monitoring, trials 
involving physiotherapy and virtual clinics were also iden-
tified, although these have previously been used in trials 
in CF.20
Ongoing studies including CFHealthHub12 and Project 
Fizzyo13 aim to address adherence in CF through the use 
of digital technology. Project Fizzyo combines the use of 
Fitbit exercise trackers with chipped airway clearance 
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devices with feedback given on technique via an App. 
Computer games were also developed to be used at 
different intervals within the study to assess their impact 
on adherence. Their aim is to improve the quality of 
airway clearance and reduce treatment burden by making 
physiotherapy more enjoyable. CFHealthHub collects 
data through data tracking nebulisers, accessible to both 
clinicians and pwCF to provide an objective measure of 
adherence. This, if handled sensitively, aims to enable 
clinicians to support patients more appropriately and 
improve adherence. Additional online supportive tools 
such as education, problem- solving and goal setting are 
available for patients.
The patient’s view is paramount in guiding future 
research and a strength of this study was that it addressed 
an area considered a priority by the CF community. 
Perspectives of both the patient and clinical CF commu-
nity were sought to give a deeper understanding of the 
issues affecting adherence. We had global reach with 
a large number of responses with an almost equal split 
between the HCP and patient community. Thematic anal-
ysis was beneficial as it allowed for a more in- depth anal-
ysis of this research question. Third, public and patient 
involvement was maintained throughout the study and 
were part of the steering group as well as through manu-
script preparation. In addition, the survey was anony-
mous which may have encouraged openness and honesty 
in the participants’ responses.
We have identified several limitations to this study. 
First, we acknowledge that self- reporting of adherence is 
subject to both recall and social desirability bias. Also, the 
demographics and opinions of people who did not take 
part are unknown. This may be of particular relevance as 
the surveys were largely promoted on digital platforms. 
Groups which either chose not to use these platforms 
or do not have access may not share the same views as 
those who chose to engage in the survey, especially in 
relation to the use of digital technologies. However, due 
to the relatively young demographic of pwCF this group 
is more likely to be familiar with using these platforms in 
their everyday lives. In addition, although a structured 
approach was taken for data analysis the nature of the 
data means that the data will always require a degree of 
subjective interpretation. Finally, the majority of respon-
dents were from the UK where healthcare is universal 
and free at the point of use. However, we feel though that 
the results are still generalisable to all countries where 
digital technologies are accessible.
CONCLUSION
Adherence to treatment is crucial but it is often subop-
timal and difficult for pwCF to achieve. Through this exer-
cise, we have shared the opinions of the CF community 
in relation to adherence, the challenges faced and what 
role digital technology has in promoting adherence. We 
hope that this research will provide first a deeper insight 
into the current challenges, as well as demonstrate areas 
for future research. This study would recommend further 
trials looking at methods of improving CF patient care 
through the three key themes identified in our analysis: 
support, motivation and technology. In particular, trials 
looking at reducing treatment burden or the role of 
CF specific App- based technology to manage their CF 
care. However, researchers should be mindful that in a 
condition where treatment burden and time pressures 
are considerable, any interventions should not add addi-
tional demands and instead focus on simplifying care 
and reducing treatment burden.
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